# Lymphadenopathy

Use nodal distribution, trajectory, systemic findings, and targeted testing to separate self-limited reactive disease from bacterial infection, granulomatous disease, autoimmune disease, and malignancy; escalate persistent, high-risk, or unexplained presentations to tissue diagnosis without relying on nondiagnostic needle sampling.

**Clinical question:** How should clinicians evaluate lymphadenopathy and select patients for observation, targeted testing, imaging, or biopsy?

Updated: 2026-09-16T01:19:28.379543+00:00

## What matters in practice
- Palpable cervical, axillary, and inguinal nodes are common in healthy children, whereas palpable supraclavicular, epitrochlear, iliac, or popliteal nodes are abnormal and warrant directed evaluation. [5]
- Use node distribution, local infectious symptoms, fever pattern, respiratory symptoms, bruising, bone or limb pain, and constitutional features to select the initial diagnostic branch rather than ordering a uniform laboratory panel. [5][18]
- Escalate evaluation for a node larger than 2 cm, hard or matted adenopathy, failure to respond to initial management, or lack of resolution over 4 to 6 weeks. [10][13]
- When lymphoma is a meaningful concern, obtain tissue adequate for architecture and ancillary studies; excisional biopsy is the diagnostic gold standard for unexplained lymphadenopathy. [1][4][10]
- Fine-needle aspiration can triage some cervical nodes, but a negative or nondiagnostic aspirate does not adequately exclude lymphoma when clinical suspicion remains high. [3][4]

## Identify presentations that require immediate escalation

Distribution and associated findings determine urgency more reliably than node palpation alone.

Start by separating localized from generalized adenopathy and by identifying nodal stations that are intrinsically concerning. Cervical, axillary, and inguinal nodes are commonly palpable in otherwise healthy children; a palpable supraclavicular, epitrochlear, iliac, or popliteal node should instead trigger evaluation for pathologic disease. [5]

Move promptly to a malignancy, systemic infection, or inflammatory evaluation when adenopathy accompanies persistent or recurrent fever, easy bruising or epistaxis, cough, limp or limb pain, or other systemic symptoms. These findings redirect the differential toward leukemia, lymphoma, mediastinal or hilar disease, tuberculosis or fungal infection, and collagen vascular disease rather than uncomplicated local reactivity. [5][18]

Treat a node larger than 2 cm, hard, matted, or nonresponsive to therapy as an active-workup presentation. Persistence without resolution for 4 to 6 weeks is a biopsy trigger in pediatric guidance; persistent neck lymphadenopathy beyond 2 to 4 weeks also merits urgent specialty investigation. [10][13][15]
- Ask specifically about sore throat, cough, recurrent fever, bleeding symptoms, limb or bone pain, and local skin, dental, or upper-respiratory symptoms; each changes the targeted differential. [5]
- Document exact nodal stations and whether disease is localized or generalized before selecting imaging or tissue sampling. [5][18]
- Do not reassure solely on the basis of a prior benign fine-needle aspiration when the node remains high risk clinically. [4]

*Clinical patterns that should change the diagnostic pathway. [5][10][13][18]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Palpable supraclavicular, epitrochlear, iliac, or popliteal node | Abnormal nodal distribution. [5] | Perform directed assessment for systemic, malignant, or regional disease rather than routine observation. [5][18] |
| Persistent/recurrent fever, bruising or epistaxis, cough, limp, or limb pain | Raises concern for infection, mediastinal or hilar disease, leukemia, malignancy, or collagen vascular disease. [5] | Undertake focused clinical and laboratory/imaging evaluation based on the associated syndrome. [5][18] |
| Node >2 cm, hard, matted, or unresponsive to therapy | High-risk phenotype requiring active workup. [10] | Plan diagnostic escalation and consider tissue diagnosis. [10][13] |
| No resolution by 4-6 weeks | Persistent adenopathy meets a pediatric biopsy consideration threshold. [13] | Refer for definitive diagnostic evaluation and select biopsy method according to the suspected diagnosis. [1][13] |

## Build the workup around distribution and the dominant clinical syndrome

History, examination, preliminary laboratories, and imaging narrow the differential before biopsy. [18]

For localized adenopathy, examine the drainage territory and seek a corresponding focal process. Localized inflammatory lymphadenitis is typically bacterial and may be acute, chronic, pyogenic, or granulomatous; the next diagnostic step should distinguish a regional infection from granulomatous disease or a noninfectious neck mass. [5]

For generalized adenopathy, prioritize systemic branches: viral or other infection, autoimmune or collagen vascular disease, and hematologic malignancy. The history should actively elicit constitutional symptoms and respiratory, bleeding, and musculoskeletal findings because these are discriminators for infectious mononucleosis, tuberculosis or fungal infection, mediastinal/hilar adenopathy, leukemia, and inflammatory disease. [5][18]

Use imaging to answer a procedural question, not as a substitute for diagnosis. Ultrasonography can support evaluation of head and neck nodes and guide needle sampling; if mediastinal nodes require sampling, endoscopic ultrasound-guided fine-needle aspiration biopsy has been reported as accurate and safe for establishing a primary diagnosis or staging lung cancer. [16][19] In a child with suspicious peripheral adenopathy, imaging should inform the safest high-yield tissue target and the need for multidisciplinary planning. [6]
- Localized cervical adenopathy with a regional inflammatory source: evaluate and manage the source while tracking objective node trajectory. [5]
- Cough or suspected thoracic disease: evaluate for tuberculosis, fungal infection, mediastinal mass, or hilar adenopathy. [5]
- Bruising, epistaxis, limb pain, or persistent systemic symptoms: prioritize a hematologic or malignant process and avoid delaying definitive evaluation with repeated empiric treatment. [5][10]
- Suspected autoimmune disease or persistent unexplained adenopathy: include systemic lupus erythematosus and Kikuchi-Fujimoto disease in the differential when clinicopathologic features fit. [2][23]

### Persistent cervical adenopathy without a clear bacterial source

Do not continue serial antibiotics when the phenotype remains unexplained or the node recurs after transient improvement. In a reported Kikuchi-Fujimoto disease case, multiple antibiotic courses were ineffective and short steroid courses produced only brief improvement before excisional biopsy established the diagnosis. [2]

Kikuchi-Fujimoto disease can mimic lymphoma, tuberculosis, nontuberculous mycobacterial infection, systemic lupus erythematosus, HIV infection, infectious mononucleosis, cat-scratch disease, Kawasaki disease, and toxoplasmosis. It most often involves cervical nodes but can occur across ages, sexes, races, and nodal sites; diagnosis is made on lymph node tissue. [23]
- Consider Kawasaki disease among children whose cervical lymphadenopathy is accompanied by compatible systemic features. [9]
- When pathology shows necrotizing lymphadenitis, correlate with lupus assessment because some patients with Kikuchi-Fujimoto disease have positive lupus laboratory studies or later develop systemic lupus erythematosus. [23]

*Etiologic branches and discriminators for pediatric lymphadenopathy. [5][9][23]*

| Branch | Discriminating findings | Actionable next step |
| --- | --- | --- |
| Localized infectious lymphadenitis | Regional drainage-area symptoms or findings; lymphadenitis may be pyogenic or granulomatous. [5] | Evaluate the regional source and distinguish acute bacterial from chronic granulomatous disease. [5] |
| Systemic infection or thoracic disease | Persistent/recurrent fever, cough, sore throat, or generalized adenopathy. [5] | Target testing and imaging toward mononucleosis, tuberculosis, fungal infection, mediastinal mass, or hilar disease according to the syndrome. [5] |
| Hematologic malignancy | Easy bruising, epistaxis, limp or limb pain, persistent fever, or concerning nodal features. [5][10] | Expedite hematologic evaluation and obtain adequate tissue when lymphoma is suspected. [4][13] |
| Kikuchi-Fujimoto disease or autoimmune disease | Persistent adenopathy that clinically or radiographically mimics lymphoma; necrotizing lymphadenitis on biopsy. [23] | Use excisional tissue pathology and assess for systemic lupus erythematosus when indicated. [2][23] |
| Kawasaki disease | Cervical lymphadenopathy with a compatible inflammatory syndrome. [9] | Assess for Kawasaki disease rather than treating isolated adenitis alone. [9] |

## Choose the biopsy method that can answer the suspected diagnosis

Sampling strategy should be driven by the probability of lymphoma, infection, and need for nodal architecture.

Excisional lymph node biopsy is the gold standard for lymphadenopathy of unknown cause and for diagnosis when lymphoma remains a serious possibility. It preserves architecture and provides material for histopathology and ancillary studies; this is particularly important because fine-needle aspiration may not yield adequate tissue for lymphoma diagnosis or cytogenetic analysis. [1][4][10]

Fine-needle aspiration is a reasonable minimally invasive triage method for selected pediatric cervical nodes. Systematic-review data cited for head and neck lymphadenopathy report cancer specificity of 92% to 100% and sensitivity of 67% to 100%, but the variable sensitivity and limited tissue architecture mean that FNA cannot close the evaluation of a clinically suspicious node. [3][4]

Use an image-guided core biopsy selectively when a percutaneous outpatient specimen can answer the question; ultrasound-guided core biopsy of head and neck lymphadenopathy has high diagnostic yield and accuracy in reported experience. [16] If the clinical question is lymphoma or an architecture-dependent inflammatory process, coordinate with pathology and the proceduralist before sampling to avoid an inadequate first specimen. [1][4][6]
- Favor excision for unexplained persistent adenopathy, high clinical suspicion for lymphoma, or a prior nondiagnostic/discordant FNA result. [1][4][13]
- Use FNA as triage when a less invasive test is appropriate, but escalate when clinical concern exceeds the information provided by cytology. [3][4]
- For deep thoracic nodes, choose a procedure suited to the nodal location; endoscopic ultrasound-guided FNA biopsy is one reported safe and accurate approach for mediastinal node sampling. [19]
- Involve pediatric, surgical, pathology, and hematology-oncology teams when biopsy is being considered for suspected malignant disease. [6]

### Avoid procedural delay from false reassurance

A cytologically benign FNA result should not override an enlarging, matted, hard, or persistent node or a syndrome suggestive of lymphoma. The key limitation is not procedural safety but the possibility that cytology lacks the architecture and ancillary material required for definitive classification. [4][10]

*Practical selection of tissue sampling strategy. [1][3][4][16][19]*

| Method | Best use | Critical limitation or advantage |
| --- | --- | --- |
| Fine-needle aspiration | Initial triage of selected cervical lymph nodes. [3][4] | Minimally invasive and cost-effective, but may not provide adequate tissue for lymphoma diagnosis or cytogenetic studies. [4] |
| Ultrasound-guided core biopsy | Selected head and neck adenopathy when outpatient percutaneous tissue is appropriate. [16] | Reported safe with high diagnostic yield and accuracy. [16] |
| Excisional lymph node biopsy | Unknown-cause adenopathy, persistent high-risk nodes, or suspected lymphoma. [1][13] | Gold standard; provides nodal architecture and tissue for ancillary evaluation. [1][4][10] |
| Endoscopic ultrasound-guided FNA biopsy | Mediastinal lymph nodes requiring invasive sampling. [19] | Reported accurate and safe for staging NSCLC or establishing a primary diagnosis; select based on anatomy and clinical question. [19] |

## Set an objective follow-up endpoint instead of indefinite observation

Observation is appropriate only when the clinical phenotype remains low risk and the trajectory is improving.

At the initial visit, record node location, size, consistency, fixation or matting, associated nodal stations, and systemic findings so that follow-up can establish resolution versus persistence. Lack of resolution by 4 to 6 weeks should move the patient from surveillance to biopsy consideration; neck lymphadenopathy persisting beyond 2 to 4 weeks may require urgent ENT evaluation. [13][15]

Escalate earlier than the persistence threshold for supraclavicular or other abnormal nodal stations, nodes exceeding 2 cm, hard or matted nodes, systemic symptoms, or failure of the initial management pathway. [5][10] Repeated empiric treatment is not a substitute for tissue diagnosis when the phenotype remains discordant with a routine infectious process. [2][4]

After a diagnosis of Kikuchi-Fujimoto disease, avoid assuming all future symptoms represent recurrent lymphoma or infection; review for systemic lupus erythematosus when clinically indicated because lupus laboratory positivity and later lupus development have been described. [23] In reported cases, symptoms may resolve without therapeutic intervention after the diagnosis is established. [24]
- Use a 2- to 4-week reassessment window for unresolved neck adenopathy requiring urgent specialty investigation. [15]
- Use a 4- to 6-week resolution endpoint as a pediatric trigger to consider biopsy. [13]
- Escalate before either interval if physical examination or systemic features suggest malignancy or serious systemic disease. [5][10]

*Time-based follow-up and escalation thresholds. [10][13][15]*

| Time or trigger | Interpretation | Next step |
| --- | --- | --- |
| Persistent neck adenopathy after 2-4 weeks | Requires urgent further investigation according to neck-lump management guidance. [15] | Arrange ENT assessment and define imaging or tissue strategy. [15] |
| No resolution after 4-6 weeks | Meets a pediatric biopsy consideration criterion. [13] | Plan definitive diagnostic evaluation, usually with tissue adequate for the suspected diagnosis. [1][13] |
| At any time: >2 cm, hard, matted, or nonresponsive node | Active-workup phenotype. [10] | Do not defer diagnostic escalation solely for observation. [10][13] |

## References
1. How to use… lymph node biopsy in paediatrics — ep.bmj.com — https://ep.bmj.com/content/102/5/244
2. Persistent cervical lymphadenitis in a patient with prior thyroid cancer attributed to Kikuchi-Fujimoto disease | BMJ Case Reports — casereports.bmj.com — http://casereports.bmj.com/content/2018/bcr-2018-226457.full.pdf
3. When does an enlarged cervical lymph node in a child need excision? A systematic review - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0165587613006575
4. Assessment of lymphadenopathy in children — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S003139550200038X
5. Lymphadenopathy - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/immunology-and-microbiology/lymphadenopathy
6. Diagnostic cervical lymphadenectomy in children: a case for multidisciplinary assessment and formal management guidelines - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0165587603004993
7. Rosai‐Dorfman disease in 6‐year‐old child: Presentation, diagnosis ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/ccr3.4795
8. CASE REPORT AND CASE SERIES : Journal of Cytology — journals.lww.com — https://journals.lww.com/jocy/fulltext/2025/11001/case_report_and_case_series.3.aspx
9. Kawasaki Disease Initially Presenting as Cervical Lymphadenopathy — journals.lww.com — https://journals.lww.com/jclinrheum/fulltext/2021/04000/kawasaki_disease_initially_presenting_as_cervical.14.aspx
10. A Case of Childhood Non-Hodgkin's Lymphoma... : Indian Journal of Paediatric Dermatology — journals.lww.com — https://journals.lww.com/ijpd/fulltext/2024/25020/a_case_of_childhood_non_hodgkin_s_lymphoma.6.aspx
11. Kikuchi-Fujimoto Disease : Medicine - Ovid — journals.lww.com — https://journals.lww.com/md-journal/fulltext/2014/11040/kikuchi_fujimoto_disease__retrospective_study_of.7.aspx
12. DIFFUSE LYMPHADENOPATHY WITH EOSINOPHILIC ... — journal.chestnet.org — https://journal.chestnet.org/article/S0012-3692(24)02728-4/fulltext
13. Pediatric Cervical - AAP Publications — publications.aap.org — https://publications.aap.org/pediatricsinreview/issue-pdf/826192
14. Lymphadenopathy (Chapter 175) - AAP Publications — publications.aap.org — https://publications.aap.org/pediatriccare/book/348/chapter/5774161/Lymphadenopathy-Chapter-175
15. Scenario: Lymphadenopathy | Management | Neck lump - CKS - NICE — cks.nice.org.uk — https://cks.nice.org.uk/topics/neck-lump/management/lymphadenopathy
16. Head and Neck Lymphadenopathy: Evaluation with US-guided ... — pubs.rsna.org — https://pubs.rsna.org/doi/10.1148/radiol.2241010602
17. Mediastinal Lymphadenopathy in the National Lung Screening Trial ... — pubs.rsna.org — https://pubs.rsna.org/doi/pdf/10.1148/radiol.210522
18. Lymphadenopathy: Differential Diagnosis and Indications for ... — publications.aap.org — https://publications.aap.org/pediatricsinreview/article/45/8/429/198003/Lymphadenopathy-Differential-Diagnosis-and
19. Evaluation of Mediastinal Lymphadenopathy with Endoscopic US ... — pubs.rsna.org — https://pubs.rsna.org/doi/10.1148/radiology.219.1.r01ap44252
20. Volume 45 Issue 8 | Pediatrics In Review | American Academy of Pediatrics — publications.aap.org — https://publications.aap.org/pediatricsinreview/issue-pdf/1702594
21. Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update — ascopubs.org — https://ascopubs.org/doi/10.1200/JCO-25-00099
22. Axillary Lymphadenopathy in the COVID-19 Era - RSNA Journals — pubs.rsna.org — https://pubs.rsna.org/doi/pdf/10.1148/rg.220045
23. Kikuchi-Fujimoto Disease in a 30-Year-Old Caucasian Female - PMC — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pmc/articles/2811397
24. Kikuchi-Fujimoto Disease In the United States: Clinical and Laboratory Characteristics and Outcomes | Blood | American Society of Hematology — ashpublications.org — https://ashpublications.org/blood/article/116/21/5100/66534/Kikuchi-Fujimoto-Disease-In-the-United-States

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.